AB1168 CLINICAL AND SEROLOGICAL EVOLUTION OF RHEUMATIC PATIENTS INFECTED BY SARS-COV-2
Authors: M. De la Rubia Navarro, J. Ivorra Cortés, E. Grau García, L. Gonzalez Puig, R. Negueroles Albuixech, I. Martínez Cordellat, F. Ortiz-Sanjuán, J. J. Fragío Gil, J. E. Oller Rodríguez, E. Vicens Bernabeu, C. Pávez Perales, S. Leal Rodriguez, L. Mas Sanchez, P. Muñoz, C. Riesco Barcena, A. V. Huaylla Quispe, I. Cánovas Olmos, C. Nájera Herranz, J. A. Román Ivorra
Journal: Annals of the Rheumatic Diseases (2022)

Background SARS-CoV-2 infection is a public health problem due to its high contagiousness and mortality. Spectrum of symptoms ranges from no symptoms to interstitial pneumonia. Patients with rheumatic disease present an increased infectious risk, especially those treated with immunosuppressants or biologic therapy. Since the beginning of the pandemic, risk of contagion and development of complications in these patients has been questioned. Objectives To describe hospitalization prevalence, seroconversion, and symptoms in patients under follow-up by the rheumatology department of a tertiary hospital. Methods Observational, cross-sectional study conducted by phone interview including patients with different diagnosis of rhematic diseases. Data about symptoms, hospital admission, serology by ELISA (when &gt;15 days of evolution), diagnosis and baseline treatment, from March 2020 to February 2021 were collected. Results Eighty-six patients with different rheumatic diseases and positive COVID-19 PCR were included (82.35% women) in Table 1. Mean age was 49.30 years (16.16). The 48.71% received biological therapy, JAK inhibitors or apremilast, with a median of 3.11 years (Q1 1,08; Q3 3,17). Secukinumab was the biological therapy most often used (24,32%), followed by Tocilizumab (13,51%). The 34,18% received DMARDs or immunosuppressors, with a median of 5.09 years (Q1 12,25; Q3 11.09). The most frequent symptoms were asthenia (72.15%), headache (66.23%) and cough (59.49%). Nine patients (11.25%) were admitted to hospital, eight of them (10%) for pneumonia. Three of them were admitted to intensive care and one died. Seroconversion occurred in 53.25%. low IgG titers were present in 2.94% and IgM persisted positive in 56.25% of this group. In 6.45% the result was indeterminate. Table 1. Diagnosis Number (%) Rheumatoid arthritis 24% Psoriasic arthritis 16% Ankylosing espondilitis 16% Systemic erythematosus lupus 8% Juvenile idiopathic arthritis 8% Systemic sclerosis 7% Behçet disease 5% Sjögren syndrome 3% Mediterranean fever 3% Sarcoidosis 1% Granulomatosis with polyangitis 1% Mixed connective tissue disease 1% Leucocitoclastic vasculitis 1% Rhupus 1% Rheumatic polymyalgia 1% Dermatomyositis 1% Cutaneous panarteritis 1% Conclusion Hospitalization and mortality rate obtained was low and the most frequent symptoms were mild. Seroconversion occurred in more than 50% of patients and the result of 6.45% was indeterminate. It’s important to highlight that since March 2020 to May 2020 IgG positive prevalence was 25%, while since September 2021 to February 2021, this prevalence increased until 57,45%. This difference is due to a modification of autoantibody detection technique since summer 2020. Disclosure of Interests None declared